Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.
复制标题
DOI：
10.3748/wjg.v22.i1.326
复制
发表时间：
2016-01
影响因子：
4.3
通讯作者：
Yigang Wang;Panpan Huang;Rong Zhang;B. Ma;Xiu-mei Zhou;Yan-Fang Sun
中科院分区：
文献类型：
--
作者：
Yigang Wang;Panpan Huang;Rong Zhang;B. Ma;Xiu-mei Zhou;Yan-Fang Sun
人类肝细胞癌（HCC）严重危害全世界人类健康。肝癌是中国最常见的癌症之一，因为慢性肝炎等肝病患者的癌症易感性最高。传统的治疗方法对晚期肝癌的疗效有限，迫切需要新的策略来改善肝癌有限的治疗选择。本文综述了腺相关病毒（AAV）和腺病毒作为肝癌基因治疗载体的基础知识、当前进展以及未来的挑战和前景。本文还回顾了使用腺病毒载体进行基因治疗的临床试验、免疫治疗、AAV 和腺病毒的毒性和免疫屏障，并提出了几种替代策略来克服使用 AAV 和腺病毒作为载体的治疗障碍。
Human hepatocellular carcinoma (HCC) heavily endangers human heath worldwide. HCC is one of most frequent cancers in China because patients with liver disease, such as chronic hepatitis, have the highest cancer susceptibility. Traditional therapeutic approaches have limited efficacy in advanced liver cancer, and novel strategies are urgently needed to improve the limited treatment options for HCC. This review summarizes the basic knowledge, current advances, and future challenges and prospects of adeno-associated virus (AAV) and adenoviruses as vectors for gene therapy of HCC. This paper also reviews the clinical trials of gene therapy using adenovirus vectors, immunotherapy, toxicity and immunological barriers for AAV and adenoviruses, and proposes several alternative strategies to overcome the therapeutic barriers to using AAV and adenoviruses as vectors.